论文信息 - Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant (RIT) regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL) - 字舞流文

Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant (RIT) regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL)

C. Craddock | S. Mackinnon | K. Peggs | A. Hunter | D. Winfield | D. Linch | R. Chopra | C. Kyriakou | A. Goldstone | E. Morris | T. Littlewood | D. Milligan | A. Parker | P. Kottaridis | K. Thomson | S. Schey | J. Tighe | G. Smith